The Experts below are selected from a list of 244563 Experts worldwide ranked by ideXlab platform
Omar Abouzid - One of the best experts on this subject based on the ideXlab platform.
-
Development of an oral once-weekly drug delivery system for HIV Antiretroviral therapy
Nature Communications, 2018Co-Authors: Ameya R. Kirtane, Omar Abouzid, Daniel Minahan, Taylor Bensel, Alison L. Hill, Christian Selinger, Anna Bershteyn, Morgan Craig, Hormoz Mazdiyasni, Cody ClevelandAbstract:The efficacy of Antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug–polymer matrices which achieved week-long systemic drug levels of the Antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting Antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide. Poor adherence to daily Antiretrovirals can significantly affect treatment efficacy, but oral long-acting Antiretrovirals are currently lacking. Here, the authors develop a once-weekly oral dosage form for anti-HIV drugs, assess its pharmacokinetics in pigs, and model its impact on viral resistance and disease epidemics.
-
development of an oral once weekly drug delivery system for hiv Antiretroviral therapy
Nature Communications, 2018Co-Authors: Ameya R. Kirtane, Omar Abouzid, Daniel Minahan, Taylor Bensel, Alison L. Hill, Christian Selinger, Anna Bershteyn, Morgan Craig, Shirley S MoAbstract:The efficacy of Antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug–polymer matrices which achieved week-long systemic drug levels of the Antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting Antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide.
Ameya R. Kirtane - One of the best experts on this subject based on the ideXlab platform.
-
Development of an oral once-weekly drug delivery system for HIV Antiretroviral therapy
Nature Communications, 2018Co-Authors: Ameya R. Kirtane, Omar Abouzid, Daniel Minahan, Taylor Bensel, Alison L. Hill, Christian Selinger, Anna Bershteyn, Morgan Craig, Hormoz Mazdiyasni, Cody ClevelandAbstract:The efficacy of Antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug–polymer matrices which achieved week-long systemic drug levels of the Antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting Antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide. Poor adherence to daily Antiretrovirals can significantly affect treatment efficacy, but oral long-acting Antiretrovirals are currently lacking. Here, the authors develop a once-weekly oral dosage form for anti-HIV drugs, assess its pharmacokinetics in pigs, and model its impact on viral resistance and disease epidemics.
-
development of an oral once weekly drug delivery system for hiv Antiretroviral therapy
Nature Communications, 2018Co-Authors: Ameya R. Kirtane, Omar Abouzid, Daniel Minahan, Taylor Bensel, Alison L. Hill, Christian Selinger, Anna Bershteyn, Morgan Craig, Shirley S MoAbstract:The efficacy of Antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug–polymer matrices which achieved week-long systemic drug levels of the Antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting Antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide.
R. Chris Rathbun - One of the best experts on this subject based on the ideXlab platform.
-
Drug interactions with Antiretrovirals and warfarin
Expert opinion on drug safety, 2010Co-Authors: Michelle D. Liedtke, R. Chris RathbunAbstract:Importance of the field: Antiretroviral therapy exhibits significant potential to alter the metabolism of other medications. Warfarin is widely used for the management of clotting disorders and is prone to drug–drug interactions that can result in subtherapeutic anticoagulation or over-anticoagulation.Areas covered in this review: The mechanism and clinical significance of drug–drug interactions between warfarin and individual Antiretrovirals are discussed. Literature searches were conducted in August of 2009 using multiple databases including Medline (1950 – 2009), EMBASE (1980 – 2009), International Pharmaceutical Abstracts (1970 – 2009) and the Cochrane Database of Systematic Reviews. The following search terms were utilized: warfarin, HIV, Antiretroviral, drug interaction, protease inhibitor (PI), non-nucleoside reverse-transcriptase inhibitor (NNRTI), cytochrome P450 (CYP450), CYP2C9 and individual Antiretrovirals by name. The manufacturers of PIs and NNRTIs were also contacted regarding unpublished ...
-
Warfarin–Antiretroviral Interactions
The Annals of pharmacotherapy, 2009Co-Authors: Michelle D. Liedtke, R. Chris RathbunAbstract:Objective:To review the literature for information regarding interactions between warfarin and Antiretroviral agents and evaluate the clinical significance of these interactions.Data Sources:Primary literature was identified through a search of MEDLINE (1950–July 2008) and International Pharmaceutical Abstracts (1970–July 2008) using individual Antiretroviral drug names and the following key search terms: warfarin, Antiretroviral, protease inhibitor, nonnucleoside reverse transcriptase inhibitor, cytochrome P450,2C9, HIV, and drug interactions. Relevant abstracts from infectious disease and HIV conferences (2005–2008), reference citations from relevant articles, and manufacturers' product information were also reviewed.Study Selection and Data Extraction:All English-language articles identified through the data search were examined. Studies and reports addressing warfarin interactions with Antiretrovirals, CYP2C9 polymorphism, and Antiretroviral CYP2C9 effects were evaluated. A total of 12 case reports we...
Cody Cleveland - One of the best experts on this subject based on the ideXlab platform.
-
Development of an oral once-weekly drug delivery system for HIV Antiretroviral therapy
Nature Communications, 2018Co-Authors: Ameya R. Kirtane, Omar Abouzid, Daniel Minahan, Taylor Bensel, Alison L. Hill, Christian Selinger, Anna Bershteyn, Morgan Craig, Hormoz Mazdiyasni, Cody ClevelandAbstract:The efficacy of Antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug–polymer matrices which achieved week-long systemic drug levels of the Antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting Antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide. Poor adherence to daily Antiretrovirals can significantly affect treatment efficacy, but oral long-acting Antiretrovirals are currently lacking. Here, the authors develop a once-weekly oral dosage form for anti-HIV drugs, assess its pharmacokinetics in pigs, and model its impact on viral resistance and disease epidemics.
Shirley S Mo - One of the best experts on this subject based on the ideXlab platform.
-
development of an oral once weekly drug delivery system for hiv Antiretroviral therapy
Nature Communications, 2018Co-Authors: Ameya R. Kirtane, Omar Abouzid, Daniel Minahan, Taylor Bensel, Alison L. Hill, Christian Selinger, Anna Bershteyn, Morgan Craig, Shirley S MoAbstract:The efficacy of Antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug–polymer matrices which achieved week-long systemic drug levels of the Antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting Antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide.